Garrick joined Belharra Therapeutics in January 2022 as Director, Platform Chemistry. Most recently, he was Associate Director, Chemistry at Inception Therapeutics where he played a role in the creation of several early-stage discovery companies including Lycia Therapeutics and Belharra Therapeutics before deciding to join Belharra. Garrick has nearly 20 years of experience in the biotech industry working in the areas of oncology and inflammation. Prior to Inception, Garrick was Principal Scientist at Effector Therapeutics where he developed translation regulators for the treatment of cancer. Before Effector, he spent 10 years at Celgene developing kinase inhibitors for the treatment of cancer and inflammation and 1 year at Abbott Laboratories developing Akt kinase inhibitors for the treatment of cancer.
Garrick received his BS in Chemistry from the University of Wisconsin, Madison and his Ph.D. in Organic Chemistry from the University of California, Irvine.